forms of treatment

KsD up to date: messages and news from all over the world 

By |2023-03-21T14:11:53+01:0012. January 2022|Categories: causes, diagnosis, forms of treatment, prevention|

With the beginning of the New Year, the team of the project "Knowledge stopps Dementia" would like to refer on a regular base to current contributions from the world wide web which have a close relation to our core topic, the lifestyle-oriented and self-responsible prevention and treatment of dementia-related diseases. The opinions expressed in the following articles should serve as a stimulus for critical discussion. They do not necessarily correspond to the positions we hold, but in all cases, they enrich the basis for discussion. Occasionally, we also refer to current freely available studies at the end - make up your own mind! 

Recent study shows: the MIND diet protects against cognitive decline, even independently of the pathological changes in the Alzheimer’s brain

By |2023-03-21T14:11:53+01:0017. November 2021|Categories: forms of treatment, nutrition, prevention|

An intriguing question for Alzheimer's researchers is the fact that some patients manage to maintain good cognitive function despite severe brain lesions (anatomical anomaly in parts of the brain). Thus, there seems to be no correlation between the deposition of amyloid plaques and cognitive changes such as memory loss, planning difficulties, behavioral disturbances, and others.  

Can anticholinergic medications increase the risk of mild cognitive impairment?

By |2023-03-21T14:11:53+01:006. October 2021|Categories: causes, forms of treatment, prevention|

During my medical residency in neurology at the Hospital of Federal Fluminense University (UFF) in Rio de Janeiro/Brazil we often faced the following question: some medications commonly prescribed in routine neurology practice (for patients with Parkinson's syndrome, depression or urinary alterations) inhibited the neurotransmitter acetylcholine, important for the formation and maintenance of memory. Since one of the proposals for the pharmacological treatment of Alzheimer's disease is precisely to increase the concentration of acetylcholine in the brain, the use of drugs that inhibit this neurotransmitter seemed contradictory and threatening to us.

Optimal Brain Health through Integrative Functional Medicine

By |2023-03-21T14:11:54+01:0014. September 2021|Categories: causes, forms of treatment, prevention|

With the project "Knowledge stops Dementia", the German Foundation for Health Information and Prevention (Deutsche Stiftung für Gesundheitsinformation und Prävention DSGiP), together with the Academy for Human Medicine (Akademie für menschliche Medizin), presents a broad spectrum of lifestyle-oriented measures for the prevention and therapy of Alzheimer's disease. In addition to Alzheimer's dementia, however, other neurodegenerative diseases such as multiple sclerosis and Parkinson's disease also pose a major challenge for those affected, their relatives and, ultimately, the healthcare system, since the prospect of a cure through pharmaceutical approaches is still a long way in the future. But the good news is, individualized lifestyle concepts seem to be effective also in these diseases.

New Alzheimer’s drug aducanumab: far-reaching implications of a controversial approval

By |2021-07-12T20:28:44+02:0013. July 2021|Categories: clinical trial, forms of treatment|

Positive news from clinical Alzheimer's research is rare. In hardly any other indication do pharmaceutical companies have to accept as many setbacks as here. To date, pharmacological approaches to treating Alzheimer's have been almost uniformly unsuccessful, with more than 400 failed clinical trials. Since 2002, there has been no new approval in the field of neurodegenerative diseases.     That changed on June 7, 2021, when the drug Aducanumab, from U.S. biotech Biogen (and its Japanese research partner Eisai), was approved by the U.S. Food and Drug Administration (FDA) for the treatment of Alzheimer's disease. The drug, which is administered intravenously to patients, will be available in the U.S. under the trade mark Aduhelm.     Aduhelm works on the basis of passive immunization. It is a monoclonal antibody that targets amyloid-ß, a protein characteristic of Alzheimer's disease. These amyloid-ß proteins make up the deposits in the brain, known as plaques, which are associated with the destruction of neurones. Aduhelm's mechanism of action is based on promoting the breakdown of β-amyloid, thereby reducing the harmful plaques.  

Galactose as a therapeutic sugar alternative for Alzheimer’s dementia?

By |2021-06-22T10:34:10+02:0023. June 2021|Categories: causes, forms of treatment, nutrition, prevention|

It has been known for quite some time that a disturbance in blood glucose and insulin metabolism plays a central role not only in diabetes, but also in Alzheimer's disease. When insulin, which is important for glucose utilization, can no longer work properly due to missing or damaged insulin receptors, the so-called insulin resistance occurs. This also applies to the brain, where it is called cerebral insulin resistance. If this occurs, our central nervous system may experience an energy deficiency despite high glucose levels in the blood. The resulting starvation state of the brain gradually leads to the cessation of its specific functions and the death of brain cells, which is particularly noticeable in the impairment of memory. Therefore, maintaining or restoring the energy metabolism of the brain is of crucial importance, especially at the beginning of Alzheimer's disease.   

Clinical trial proves potential reversal of cognitive decline in early Alzheimer’s disease

By |2021-09-06T13:18:02+02:002. June 2021|Categories: clinical trial, forms of treatment|

It's been a long road for Dr. Dale Bredesen in Alzheimer's research: He worked for years as a scientist and studied dying brain cells, fruit flies with "Alzflymer" and transgenic mice with "Mouzheimer's." But his applications for clinical trials that could demonstrate proof of efficacy of his research concepts in patients were first rejected in 2011 and again in 2018. Instead, he published treatment successes in his patients in 2014, 2016 and 2018. Finally, in 2019, he received approval to conduct a clinical trial, which was then completed last year.  

Awakening from deep dementia: favourite music as the key to memory

By |2021-05-11T17:03:49+02:0012. May 2021|Categories: clinical trial, forms of treatment, prevention|

It seems like a miracle: a late-stage Alzheimer's patient, completely immersed in dementia and cut off from his environment and his own identity. But when he hears the sounds of familiar pieces of music selected for him from his former life, he wakes up from his apathy, starts to laugh, talk, move and becomes 'alive' again!

Early Alzheimer’s symptoms are reversible: current lifestyle intervention shows promising results

By |2021-04-21T09:52:21+02:0021. April 2021|Categories: causes, clinical trial, forms of treatment, nutrition, prevention|

The relation between lifestyle and Alzheimer’s disease has been previously described in many studies. It has become well established that lifestyle interventions can prevent the onset of the disease in about 40% (as we reported in a previous NF based on the 12 Alzheimer’s disease prevention factors listed by The Lancet commission on Dementia). The Finnish FINGER study (Finnish Geriatric Intervention Study 2015) has also already impressively shown these correlations 

Go to Top